Back to Search
Start Over
Outcomes of digoxin vs. beta blocker in atrial fibrillation: report from ESC-EHRA EORP AF Long-Term General Registry
- Source :
- Ding, W Y, Boriani, G, Marin, F, Blomström-Lundqvist, C, Potpara, T S, Fauchier, L, Lip, G Y H, ESC-EHRA EORP-AF Long-Term General Registry Investigators, Joensen, A M, Gammelmark, A, Rasmussen, L H, Dinesen, P, Riahi, S, Venø, S K, Sorensen, B, Korsgaard, A, Andersen, K & Hellum, C F 2022, ' Outcomes of digoxin vs. beta blocker in atrial fibrillation : report from ESC-EHRA EORP-AF Long-Term General Registry ', European heart journal. Cardiovascular pharmacotherapy, vol. 8, no. 4, pvab076, pp. 372–382 . https://doi.org/10.1093/ehjcvp/pvab076
- Publication Year :
- 2021
-
Abstract
- Aims The safety of digoxin therapy in atrial fibrillation (AF) remains ill-defined. We aimed to evaluate the effects of digoxin over beta-blocker therapy in AF. Methods and results Patients with AF who were treated with either digoxin or a beta blocker from the ESC–EHRA EORP AF (European Society of Cardiology–European Heart Rhythm Association EURObservational Research Programme Atrial Fibrillation) General Long-Term Registry were included. Outcomes of interest were all-cause mortality, cardiovascular (CV) mortality, non-CV mortality, quality of life, and number of patients with unplanned hospitalizations. Of 6377 patients, 549 (8.6%) were treated with digoxin. Over 24 months, there were 550 (8.6%) all-cause mortality events and 1304 (23.6%) patients with unplanned emergency hospitalizations. Compared to beta blocker, digoxin therapy was associated with increased all-cause mortality [hazard ratio (HR) 1.90 (95% confidence interval, CI, 1.48–2.44)], CV mortality [HR 2.18 (95% CI 1.47–3.21)], and non-CV mortality [HR 1.68 (95% CI 1.02–2.75)] with reduced quality of life [health utility score 0.555 (±0.406) vs. 0.705 (±0.346), P Conclusion Poor outcomes related to the use of digoxin over beta-blocker therapy in terms of excess mortality and reduced quality of life are associated with the presence of other risk factors rather than digoxin per se. The choice of digoxin or beta-blocker therapy had no influence on the incidence of unplanned hospitalizations.
- Subjects :
- Quality of life
medicine.medical_specialty
Registry
Digoxin
Rate control
medicine.drug_class
Permanent AF
Adrenergic beta-Antagonists
Heart failure
030204 cardiovascular system & hematology
Digoxin/adverse effects
03 medical and health sciences
0302 clinical medicine
Internal medicine
EORP-AF
Atrial Fibrillation
medicine
CKD
Humans
Pharmacology (medical)
030212 general & internal medicine
Registries
Mortality
Beta blocker
Hospitalizations
Adrenergic beta-Antagonists/adverse effects
business.industry
Incidence (epidemiology)
Confounding
Atrial fibrillation
medicine.disease
3. Good health
Cardiology
Quality of Life
Cardiology and Cardiovascular Medicine
business
Atrial Fibrillation/complications
Kidney disease
medicine.drug
Subjects
Details
- ISSN :
- 20556845
- Volume :
- 8
- Issue :
- 4
- Database :
- OpenAIRE
- Journal :
- European heart journal. Cardiovascular pharmacotherapy
- Accession number :
- edsair.doi.dedup.....78d8ea8bd3519ecbf5ff250bb8ff0931